A colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma - a case report with EGFR copy number analysis
© Huang et al; licensee BioMed Central Ltd. 2010
Received: 30 July 2010
Accepted: 20 October 2010
Published: 20 October 2010
Small cell neuroendocrine carcinoma (SNEC) of maxillary sinus is a rare and aggressive malignancy. A tumor with squamous cell carcinoma, adenocarcinoma and SNEC co-existence is extremely rare.
We present a colliding tumor of squamous cell, adenocarcinoma and SNEC in maxillary sinus. The clinical features, diagnosis and EGFR flourescence in situ hybridization (FISH) study are presented. A 52-year-old female had a 1-month history of progressing left cheek swelling and purulent rhinorrhea. Magnetic resonance imaging showed a tumor involving left maxilla and orbital floor. Excision of tumor was done and the defect was reconstructed with free flap. The pathology revealed a malignant tumor composed of squamous cell carcinoma, adenocarcinoma and SNEC components. EGFR FISH study showed no gene amplification in 3 components of this tumor. The tumor progressed rapidly and the patient expired at 8 months after surgery.
A colliding tumor of squamous cell, adenocarcinoma and neuroendocrine carcinoma in maxillary sinus was aggressive in behavior and the treatment response was poor due to the complexity of tumor.
Carcinoma of the paranasal sinuses accounts for about 0.3% of all cancers . Most of the malignancies in paranasal sinus is squamous cell carcinoma (SCC) and followed by adenocarcinoma. Small cell neuroendocrine carcinoma (SNEC) is a rare tumor in head and neck region and it occurs most frequently in larynx . Paranasal sinuses are uncommon primary sites for the occurrence of extrapulmonary SNECs. Only small series and case reports were available to date for primary sinonasal tract SNEC . Foci of squamous or glandular differentiation in SNECs were occasionally noted [4, 5]. The collision of three components (squamous cell, adenocarcinoma and neuroendocrine cells) in a solid tumor was very rare. Only two reports of combined adenosquamous and large-cell neuroendocrine carcinoma were reported in the literature [6, 7].
Despite extensive treatment, SNECs in head and neck had poor prognosis and high rates of recurrence and distant metastasis . Epidermal growth factor receptor (EGFR) antagonists and monoclonal antibodies were found to have promising results in non-small lung cancer and colon cancer [8, 9]. In head and neck SCC, several EGFR inhibitors have been studied alone or in combination with cisplatin/carboplatin and were found to have modest response rates [10, 11]. The target therapies provide new options to traditional therapies. In a tumor of three different histologies (squamous cell, adenocarcinoma and neuroendocrine cells) and aggressive in behavior, we investigated the EGFR copy number by fluorescence in situ hybridization (FISH) in each component of the tumor. The feasibility of EGFR target therapy in such a malignant tumor was discussed in the text.
FISH Assay and Analysis
EGFR copy numbers were investigated by FISH using the LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen probe (Vysis; Abbott Laboratories, Downers Grove, IL) and this was carried out using the manufacturer's protocols. In brief, section slides were incubated at 56°C overnight, deparaffined, dehydrated, and treated with 0.2 N HCl (pH 2.5) for 20 min. This was followed by 1 M sodium thiocyanate (Sigma-Aldrich Corp., St. Louis, MO) in 1 M Tris (pH 8.0) at 82°C for 20 min, and then the specimens were digested with 0.4% pepsin (Sigma-Aldrich Corp., St. Louis, MO) in 0.9% NaCl (pH 2.35) for 15 min. The samples were briefly rinsed with ddH2O and 2 × SSC between steps. After fixation in 4% formaldehyde for 5 min, each slide had the probe set applied to the selected area, and the hybridization area was covered with a plastic coverslip and sealed with a glue gun before heating at 75°C for 10 min in an OmniGene system (Hybaid Ltd., Middlesex, United Kingdom) to allow co-denaturation of the chromosomal and probe DNAs. Hybridization was then carried out in a humidified oven at 37°C for 18 hours, and this was followed by postwashing in 0.3% Nonidet P40 (BDH, England) in 2 × SSC at 55°C for 4 min, in 2 × SSC at 55°C for 5 min, and finally twice in 2 × SSC at room temperature for 5 min. After being counterstained with DAPI for 5 min, the slides were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and scored under an epifluorescence microscope using a Plan Neofluar 100 × objective (Axiophot, Zeiss, Germany) with FITC/TRITC dual and DAPI/FITC/TRITC riple pass filters (Chroma Technology Corp., Bellows Falls, VT).
Most of maxillary sinus cancer was SCC and adenocarcinoma. SNEC of the sinonasal region is the least common of the sinonasal carcinomas with neuroendocrine differentiation. The SCC or adenocarcinoma in maxillary sinus developed from the lining mucosal epithelium or metaplasia. The histogenesis of the neuroendocrine differentiated tumors is not clear. Whether those cells stem from a common pluripotent precursor or from metaplastic neuroendocrine cells is still unclear. It has been postulated that, outside the lung, this tumor is derived from the neuroendocrine APUD cells, which are widely distributed in the body. The tumors are composed of small-sized regular cells arranged in broad sheets, nests, and cords. Many of the cells contain cribriform nuclei with a fine reticular chromatin pattern and small to moderate amounts of cytoplasm . Immunohistochemical study is essential to make an adequate differential diagnosis from other malignant tumors such as lymphoma, rhabdomyosarcoma, undifferentiated nasopharyngeal carcinoma, and undifferentiated sinonasal carcinoma. SNEC has been reported to stain strongly with synaptophysin and CD56 nerve cell adhesion molecule and weakly with chromogranin A and CAM 5.2/AE-1 .
Yazawa et al. had investigated the clonality of colliding tumor which composed of adenocarcinoma, SCC and large cell neuroendocrine carcinoma . The clonality results were similar in adenomatous and squamous components and different in neuroendocrine component. There were some limitations in that study due to possible DNA fragmentations in formalin fixed tissues. However, it confirmed the adenomatous and squamous components were the same origin and classified it as a colliding tumor of adenosquamous carcinoma (ASC) and neuroendocrine carcinoma. In the literature, ASC is an unusual neoplasm and often misdiagnosed . In our patient, the colliding tumor could originate from a mixture of ASC and the SNEC which gives the tumor a feature of 3 different histologies.
The treatment of SNECs varied considerably over time which includes surgery followed by radiotherapy, concurrent chemo-radiotherapy with or without surgery, and chemotherapy with cisplatin and eoposide followed by radiation or surgery . No consensus yet exists about its treatment. The management of maxillary sinus ASC is also controversial due to its rarity. The prognosis in cases of head and neck SNEC and ASC is very poor because of the high metastatic rate observed. [3, 14] In our patient, the tumor recurred and metastasized rapidly after surgery. Its response to chemotherapy was poor. The diverse components of the tumor could possibly account for its non-responsiveness to chemotherapy and aggressive behaviors.
Recently, EGFR targeting agents such as Cetuximab (C225, Erbitux™), a human-murine chimeric monoclonal antibody, gefitinib and erlotinib were developed. They are less toxic in side effects than cheomotherapies. In locoregionally advanced head and neck SCC, concomitant high-dose radiotherapy plus Cetuximab had been shown to improve locoregional control and reduces mortality . In chemotherapy refractory head and neck cancers, some are responsive to EGFR target treatment. However, from EGFR copy number analysis in each component of the tumor, no EGFR amplification was found. EGFR targeting agents might have limited roles in this rare tumor.
A colliding malignant tumor of SCC, adenocarcinoma and SNEC is rare in head and neck malignancies. The diagnosis of this tumor usually could be made after excision of tumor. Both adenosquamous carcinoma and SNEC have aggressive behaviors. The colliding tumor of these components also carries a poor prognosis. EGFR copy numbers in all three histologies were not increased and the efficacy of anti-EGFR target therapy could be limited in this rare malignancy.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Professor Ling-Ling Hsieh from Chang Gung University for her valuable advice and assistance. This study was supported by Grant CMRPG340381, CMRPG360701, CMRPG360851 and CMRPG371511 from Chang Gung Memorial Hospital, Grant NSC99-2314-B-182A-036-MY3 from the National Science Council and Grant DOH99-TD-C-111-006 from the Department of Health, Executive Yuan, ROC.
- Monserez D, Vlaminck S, Kuhweide R, Casselman J: Symmetrical ethmoidal metastases from ductal carcinoma of the breast, suggesting transcribrosal spread. Acta Otorhinolaryngol Belg. 2001, 55: 251-257.PubMed
- Mills SE: Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol. 2002, 15: 264-278. 10.1038/modpathol.3880522.View ArticlePubMed
- Mineta H, Miura K, Takebayashi S, Araki K, Ueda Y, Harada H, Misawa K: Immunohistochemical analysis of small cell carcinoma of the head and neck: a report of four patients and a review of sixteen patients in the literature with ectopic hormone production. Ann Otol Rhinol Laryngol. 2001, 110: 76-82.View ArticlePubMed
- Chen DA, Mandell-Brown M, Moore SF, Johnson JT: "Composite" tumor--mixed squamous cell and small-cell anaplastic carcinoma of the larynx. Otolaryngol Head Neck Surg. 1986, 95: 99-103.PubMed
- Gnepp DR: Small cell neuroendocrine carcinoma of the larynx. A critical review of the literature. ORL J Otorhinolaryngol Relat Spec. 1991, 53: 210-219.View ArticlePubMed
- Noske A, Pahl S: Combined adenosquamous and large-cell neuroendocrine carcinoma of the gallbladder. Virchows Arch. 2006, 449: 135-136. 10.1007/s00428-006-0171-z.View ArticlePubMed
- Yazawa T, Ishii H, Ito T, Yoshiike Y, Ogawa N, Okudela K, Hayashi H, Suzuki T, Mitsui H, Ikeda M, Kitamura H: Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. Pathol Int. 2003, 53: 58-65. 10.1046/j.1440-1827.2003.01428.x.View ArticlePubMed
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004, 101: 13306-13311. 10.1073/pnas.0405220101.PubMed CentralView ArticlePubMed
- Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008, 19: 717-723. 10.1093/annonc/mdm492.View ArticlePubMed
- Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003, 21: 1980-1987. 10.1200/JCO.2003.10.051.View ArticlePubMed
- Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004, 22: 77-85. 10.1200/JCO.2004.06.075.View ArticlePubMed
- Rejowski JE, Campanella RS, Block LJ: Small cell carcinoma of the nose and paranasal sinuses. Otolaryngol Head Neck Surg. 1982, 90: 516-517.PubMed
- Avitia S, Osborne RF: Blindness: a sequela of sinonasal small cell neuroendocrine carcinoma. Ear Nose Throat J. 2004, 83: 530-532.PubMed
- Alos L, Castillo M, Nadal A, Caballero M, Mallofre C, Palacin A, Cardesa A: Adenosquamous Carcinoma of the head and neck: criteria for diagnosis in a study of 12 cases. Histopathology. 2004, 44: 570-579. 10.1111/j.1365-2559.2004.01881.x.View ArticlePubMed
- Babin E, Rouleau V, Vedrine PO, Toussaint B, de Raucourt D, Malard O, Cosmidis A, Makaeieff M, Dehesdin D: Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol. 2006, 120: 289-297. 10.1017/S0022215106000594.View ArticlePubMed
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.